Relative survival reflects the survival cancer patients would be expected to have in the absence of competing causes of death and is commonly reported by cancer registries. It is computed as the ratio between absolute survival of cancer patients and expected survival in the absence of cancer. The latter is estimated from life tables of the general population ([@bib4]), mostly by the so-called Ederer II method ([@bib5]) or Hakulinen\'s method ([@bib8]).

The variance of relative survival is a function of the absolute and expected survival as well as the variance of absolute survival and expected survival and the covariance between absolute and expected survival (see [Appendix](#app1){ref-type="app"}). In the computation of the standard error of relative survival it is commonly assumed that the variance of expected survival is zero (which implies that the covariance with absolute survival is also zero), as the database underlying the population life tables is usually very large. Therefore, the standard error is commonly computed as the ratio between the standard error of absolute survival and the expected survival ([@bib10]; [@bib6]). If the assumption of zero variance of expected survival does not hold, however (for reasons discussed below), then the variance of relative survival may be over- or underestimated, depending, among other factors, on the relative magnitude of the variance of expected survival and the covariance of absolute and expected survival (see [Appendix](#app1){ref-type="app"} ).

[@bib2] empirically assessed the validity of the commonly used standard error definition (ignoring variance of expected survival) using data from the nationwide Finnish Cancer Registry. They computed conventional and bootstrap standard errors for 5- and 10-year non-standardised (crude) absolute, expected and relative survival for patients with 25 common forms of cancer in Finland in 1989. Expected survival was computed according to Hakulinen\'s method. When applying the conventional standard error definition, standard errors were overestimated by up to 17% for 5-year and 32% for 10-year non-standardised relative survival. This overestimation can be explained by non-zero standard errors for expected survival that may arise, as the expected survival is still subject to random variation due to random variation of the age distribution of the sample. Furthermore, absolute and expected survival may often be positively correlated, as survival typically decreases with increasing age in cancer patients as well as in the general population. To overcome the overestimation of standard errors, [@bib2] suggested to compute bootstrap standard errors for relative survival and provided extensions of publicly available *SAS* macros for survival analysis (*period* and *periodh*; [@bib1]) that allow computing these standard errors.

In addition to non-standardised relative survival, age-standardised relative survival is commonly reported to compare survival across populations with different age structures. Age-standardised relative survival is commonly computed as the weighted sum of age-specific relative survival, using weights according to standard age distributions of cancer patients such as the International Cancer Survival Standard (ICSS; [@bib14]; [@bib3]). Standard errors of these survival estimates are defined as the square root of the sum of the squared weighted age-stratified standard errors of relative survival. Thus, the same assumptions as in the computation of the standard error of non-standardised relative survival apply, but now on the level of the age-stratified survival estimates. As the age variability within these age groups is much smaller, the correlation of absolute and expected survival and the standard error of expected survival may be much lower. Thus, the conventional method to estimate the standard error of age-standardised relative survival might result in more accurate estimates.

To our knowledge, however, no previous study has assessed the validity of the conventional method in the context of age-standardised survival. This is particularly important, as age-standardised estimates are frequently reported. In addition, the validity of the method in the context of the Ederer II method, which is now increasingly applied, has not been investigated yet. Thus, the aim of this paper was to assess the validity of the conventional method to estimate standard errors of age-standardised relative survival and to estimate the accuracy of the conventional method when expected survival is computed according to either the Ederer II method or Hakulinen\'s method. Bootstrap standard errors of non-standardised and age-standardised relative survival were compared with standard errors computed according to the standard procedure. In addition, the random error of non-standardised expected survival and the correlation between non-standardised expected and absolute survival were estimated to check the assumptions of negligible variation of expected survival and negligible correlation.

Materials and methods
=====================

The analysis was based on data from the population-based Finnish Cancer Registry, which has been operating for more than 50 years, covers the whole population of Finland (about 5.4 million people), and is well known for its data quality and completeness ([@bib13]). Patients aged 15 years or older with a first diagnosis of one of 25 common forms of cancer between 1989 and 1993 were included. These years of diagnosis were selected to ensure comparability with results of our earlier work on non-standardised relative survival, which had pertained to patients diagnosed in 1989, the most recent cohort of patients for whom 10-year survival had been completed at the time of our previous analysis. To avoid problems due to sparse data due to age stratification, the current analysis was extended to 5 years of diagnosis, that is, 1989--1993. Reproducibility of the results was assessed by repeating all analyses separately for patients diagnosed between 1979 and 1983 and between 1984 and 1988. As the patterns regarding the standard errors for non-standardised and age-standardised survival were generally very similar, results for these groups of patients are not shown separately.

For each cancer site, 5- and 10-year non-standardised absolute, expected and relative survival and age-standardised relative survival and the corresponding standard errors in % units were computed. Expected survival was calculated based on age-, sex- and calendar period-specific population life tables of Finland using both Hakulinen\'s ([@bib8]) and the Ederer II method ([@bib5]). Because available life tables of Finland were limited to ages up to 95 years, expected survival for cancer patients older than 95 years were based on the survival estimate of the general population of age 95 years. Age-standardised survival was computed as weighted average of age-specific survival, defining the age groups (15--44, 45--54, 55--64, 65--74, 75+ years) according to the ICSS ([@bib3]) and the weights for each site and gender proportional to the numbers of patients at diagnosis in these age groups. The definition of weights was done in order to make the age-standardised and non-standardised survival figures mutually comparable.

For the calculation of the standard error of non-standardised and age-standardised relative survival, two methods were employed. The first method followed common practice in the analysis of population-based cancer registry data: Standard errors of relative survival were obtained by dividing the standard errors of absolute survival, which were computed according to Greenwood\'s method ([@bib7]), by the expected survival ([@bib4]). For age-standardised survival, the ratio is computed between age-stratified estimates. The standard error of the age-standardised relative survival is estimated by the square root of the sum of the squared weighted age-stratified standard errors of relative survival. In the second method, the standard errors of relative survival were estimated by non-parametric bootstrap analysis as the standard deviation of the respective point estimate in 10 000 bootstrap samples. Each bootstrap sample was obtained by sampling with replacement from the patient population for a given cancer in the cancer registry, the same number of patients as in the original data set. Conventional and bootstrap standard errors were compared by computing ratios between the estimates.

To investigate the assumption of negligible standard error of expected survival and negligible correlation between absolute and expected survival, standard errors for non-standardised expected survival were estimated by bootstrapping, and Pearson\'s correlation coefficients of the point estimates of non-standardised absolute and expected survival in the bootstrap samples were calculated.

Results
=======

[Table 1](#tbl1){ref-type="table"} shows the numbers of patients and their age distribution for each cancer site. Breast cancer was the most commonly diagnosed cancer in 1989--1993 (*N*=13 278), followed by lung (*N*=10 127), colorectal (*N*=8620) and prostate cancer (*N*=7753). Median age at diagnosis ranged from 34 years for testicular cancer to 74 years for prostate cancer.

Results for Hakulinen\'s method are shown in [Table 2](#tbl2){ref-type="table"} for 5-year survival, and in [Table 3](#tbl3){ref-type="table"} for 10-year survival. Five- and ten-year non-standardised absolute survival varied strongly by cancer site, ranging from 89.7 and 88.1% for testicular cancer to 1.8 and 1.1% for pancreatic cancer. Standard errors of 5- and 10-year absolute survival ranged from 0.25 and 2.84 to 0.18 and 2.98, respectively.

Non-standardised expected survival computed by Hakulinen\'s method was highest for testicular cancer, as these patients are on average younger than patients of the other cancer sites, and lowest for prostate cancer because of their relatively high age at diagnosis. Standard errors of 5- and 10-year non-standardised expected survival ranged from 0.13 and 0.22 for breast cancer to 0.93 and 1.53 for eye cancer. For all cancer sites, they were higher for 10-year than for 5-year survival and, although lower than standard error of absolute survival, generally not negligible.

Non-standardised absolute and expected survival was moderately positively correlated for both 5- and 10-year survival (ranges across cancer sites: 0.09--0.60 and 0.09--0.59, respectively).

Comparing standard errors of relative survival computed by the conventional and bootstrap method, conventional standard errors of 5-year non-standardised relative survival were overestimated by more than 5% for eight cancer sites and by more than 10% for Hodgkin\'s lymphoma (11%) and thyroid gland cancer (17%). Median overestimation across the 25 cancer sites was 4%. For 10-year non-standardised relative survival, overestimation was mostly larger (median: 6%). For seven cancer sites, it was larger than 10%. The highest overestimation was observed for thyroid gland cancer (26%). For age-standardised relative survival, deviations between the conventional and bootstrap standard errors were negligible (within ±1% for 16 of 25 cancer sites for 5-year survival and for 15 cancer sites for 10-year survival). Strongest overestimations were found for laryngeal cancer for 5-year (3%) and cancer of the breast, urinary bladder and corpus uteri for 10-year (3%) age-standardised relative survival.

The analysis was repeated with the computation of expected survival according to the Ederer II method ([Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}). Non-standardised expected survival computed by the Ederer II method was overall higher than the estimates computed by Hakulinen\'s method. Standard errors of 5- and 10-year non-standardised expected survival were comparable, ranging from 0.15 and 0.27 for breast cancer to 1.55 and 4.01 for gallbladder cancer, respectively.

Correlations between non-standardised absolute and expected survival, which were based on the Ederer II method, were generally lower than the correlations in the context of Hakulinen\'s method (ranges across cancer sites: 0.03--0.32 and 0.03--0.32, respectively).

Conventional standard errors of relative survival were generally smaller when computed by the Ederer II instead of the Hakulinen\'s method. Deviations between the conventional standard errors and the bootstrap standard errors of non-standardised relative survival were negligible for 5-year survival (median deviation: 2%) and small for 10-year survival (median deviation: 3%). Deviations were largest for cancer of the thyroid gland and corpus uteri for 5-year survival (4%), and for gallbladder and urinary bladder cancer (−6 and 6%) for 10-year survival. The accuracy of the standard errors of age-standardised relative survival was again higher with a median deviation of 0% for 5-year and 10-year survival, and a maximal deviation of 4 and 6%, respectively.

Discussion
==========

Our results confirm previous observations that conventional standard errors for non-standardised relative survival, which were computed according to Hakulinen\'s method, may often be substantially overestimated reaching percentage deviations of up to 28% in the examples assessed in this article. Overestimations were overall larger in case of long survival times, that is, for 10- than for 5-year survival, and in case of higher correlations between absolute and expected survival. Largest overestimations were observed for thyroid cancer and Hodgkin\'s lymphoma. Both cancer sites had the highest correlation between absolute and expected survival, which can be explained by the large age gradient in prognosis of patients with these two malignancies. We could show, however, that standard errors for age-standardised relative survival, which were computed by Hakulinen\'s method, were accurately estimated by the conventional standard error method. When using the Ederer II method, deviations of the standard errors of non-standardised relative survival were small to negligible, and standard errors of age-standardised survival were accurately estimated.

The commonly used definition of the standard error of relative survival is based on the assumption of zero standard error of expected survival. However, non-negligible standard errors for non-standardised expected survival were observed, which can be explained by the random variation of the age distribution of the sample. Furthermore, for many cancer sites, a substantial positive correlation between non-standardised absolute survival and expected survival computed by Hakulinen\'s method was observed, which can be explained by the common variation of absolute and expected survival, as both estimates decrease with increasing age. Within age groups used for age-standardisation random variation of the age distribution and, hence, variance of expected survival and covariance of absolute and expected survival is smaller.

Overestimation of the standard error of non-standardised relative survival is a consequence of random error in expected survival, along with positive covariance of absolute and expected survival ([@bib2]). Substantial overestimations were observed when expected survival was computed by Hakulinen\'s method. The age-standardisation computed as weighted averages of age-specific estimates overcomes the problem of overestimated standard errors of relative survival. When expected survival was computed by the Ederer II method, errors in the estimation of the standard errors of non-standardised relative survival were small to negligible. The difference between these two methods might be explained in part by smaller covariance of absolute and expected survival for the Ederer II than for Hakulinen\'s method, which is reflected by the smaller correlation coefficients in our bootstrap analysis.

Relative survival, computed as the ratio of absolute and expected survival, is often interpreted as an estimate of net survival when cancer was the only cause of death. However, it has been shown that this interpretation is valid only when survival with respect to cancer and survival with respect to other diseases are independent ([@bib11]). This condition is only rarely fulfilled, as both survival proportions are usually affected by common covariates such as age. Comparison of the accuracy of methods such as Ederer I, II and Hakulinen for the estimation of net survival have usually been restricted to investigations of the point estimate ([@bib12]; [@bib9]). These investigations have suggested that without applying regression modelling, the gold standard to estimate net survival may be age-standardised relative survival with expected survival computed by the Ederer II method and weights proportional to the number of patients at the beginning of the follow-up ([@bib12]). In general, the bias in the estimation of net survival is smaller when using the Ederer II method than when using the Ederer I or Hakulinen\'s method and increases for the Ederer I and Hakulinen\'s method over time ([@bib9]). Our results on the standard error of relative survival support the recommendation of the Ederer II method, as both standard errors of non-standardised and age-standardised relative survival estimates were accurately estimated by the conventional method.

Recently, a new method to estimate net survival was proposed by [@bib11]. This new method provides an unbiased estimate for net survival without any modelling. The corresponding variance estimate has already been tested for accuracy by comparison with bootstrap estimates. Results from the empirical and theoretical investigations of this method are very promising. However, the method requires the absence of censoring and it has to be shown how estimates change in case of censoring.

The accuracy of the standard error of relative survival was estimated by the ratio between the conventional and bootstrap standard error. To test whether the measurement of bias in relative terms depends on the sample size, we re-run the analysis for the two most common cancer sites (breast and lung cancer) and the two cancer sites with the largest bias (thyroid cancer and Hodgkin\'s lymphoma) using a variable proportion (1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40,  ... , 90%) of the complete data set. No indication for the dependence of relative bias on the sample size was found (data not shown).

In summary, our results show that overestimations of the standard errors can be substantially reduced by computing age-standardised survival. In age-standardised survival, the correlation between absolute and expected survival is substantially reduced. For the Ederer II method, standard errors of non-standardised and age-standardised relative survival were accurately estimated. Thus, our results support the recommendation to use the Ederer II method to estimate relative survival ratios.
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Some mathematical details
=========================

Applying the delta method, the variance of relative survival (var (*R*(*t*)) is a function of absolute (*A*(*t*)) and expected survival (*E*(*t*)) as well as the variance of absolute survival (var(*A*(*t*)) and expected survival (var(*E*(*t*)) and the covariance between absolute and expected survival cov(*A*(*t*), *E*(*t*)) ([@bib2]):

It is commonly assumed that the variance of expected survival and the covariance between absolute and expected survival are zero. Therefore, the variance of relative survival is conventionally computed using the Greenwood formula by:

The bias introduced by using the Greenwood formula is given by:

The relative bias is given by
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###### Numbers and age distribution of patients aged 15 or more years with a first diagnosis of common forms of cancer, Finland, 1989--1993

                                            **Percentiles of age distribution (years)**                  
  --------------------------------- ------- --------------------------------------------- ---- ---- ---- ----
  Oral cavity                       1913    47                                            58   68   77   83
  Oesophagus                        971     55                                            63   72   79   85
  Stomach                           4691    51                                            62   71   79   84
  Colorectal                        8620    52                                            62   71   78   84
  Liver                             1017    52                                            63   71   78   84
  Pancreas                          3291    55                                            64   72   79   84
  Larynx                            549     49                                            58   65   73   79
  Lung                              10127   55                                            62   68   75   80
  Skin melanoma                     2445    35                                            45   58   71   80
  Breast                            13278   43                                            49   60   72   80
  Urinary bladder                   3546    54                                            63   71   78   83
  Cervix                            668     37                                            47   65   76   82
  Corpus uteri                      2852    51                                            58   66   73   80
  Ovaries                           2252    44                                            54   64   73   80
  Prostate                          7753    62                                            68   74   79   84
  Testis                            329     22                                            26   34   43   56
  Kidneys                           3074    49                                            58   67   74   80
  Eye                               281     40                                            50   63   71   80
  Brain/nervous system              1486    29                                            40   54   67   75
  Thyroid gland                     1385    29                                            39   50   65   76
  Non-Hodgkin\'s lymphoma           3356    41                                            54   66   75   81
  Multiple myeloma                  1166    55                                            63   71   78   84
  Leukaemia                         1884    41                                            56   68   77   83
  Biliary passage and gallbladder   769     59                                            65   73   80   85
  Hodgkin\'s lymphoma               553     20                                            27   39   58   73

###### Non-standardised absolute, expected and relative survival and age-standardised relative survival after 5 years of patients aged 15 or more years with a first diagnosis of common forms of cancer, Finland, 1989--1993[a](#t2-fn3){ref-type="fn"}

                            **Non-standardised 5-year survival**   **Age-standardised 5-year survival**                                                                         
  ------------------------- -------------------------------------- -------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Oral cavity               51.0                                   79.7                                   64.1   1.14   1.43   0.43   0.26   1.38   1.04   63.7   1.49   1.48   1.01
  Oesophagus                5.5                                    75.5                                   7.2    0.73   0.97   0.63   0.14   0.96   1.00   6.7    0.91   0.91   1.00
  Stomach                   16.9                                   76.2                                   22.2   0.55   0.72   0.29   0.23   0.71   1.01   21.0   0.70   0.68   1.02
  Colorectal                39.4                                   77.9                                   50.5   0.53   0.68   0.20   0.29   0.66   1.03   49.7   0.69   0.67   1.02
  Liver                     3.0                                    77.3                                   3.9    0.54   0.70   0.58   0.13   0.70   1.00   3.5    0.62   0.63   0.99
  Pancreas                  1.8                                    76.9                                   2.3    0.23   0.30   0.32   0.11   0.30   0.98   2.0    0.26   0.26   1.00
  Larynx                    49.9                                   81.7                                   61.1   2.13   2.61   0.66   0.26   2.51   1.04   60.8   2.69   2.62   1.03
  Lung                      7.2                                    79.3                                   9.1    0.25   0.32   0.16   0.15   0.32   1.01   8.6    0.31   0.31   1.00
  Skin melanoma             71.0                                   87.4                                   81.3   0.92   1.05   0.32   0.38   0.98   1.07   80.5   1.09   1.08   1.01
  Breast                    72.2                                   89.2                                   80.9   0.39   0.44   0.13   0.35   0.41   1.05   80.2   0.45   0.45   1.01
  Urinary bladder           51.9                                   75.6                                   68.7   0.84   1.11   0.31   0.38   1.04   1.07   66.9   1.12   1.10   1.02
  Cervix                    48.7                                   86.4                                   56.4   1.94   2.24   0.64   0.44   2.08   1.08   53.5   2.04   2.03   1.00
  Corpus uteri              69.4                                   87.5                                   79.3   0.87   0.99   0.27   0.40   0.92   1.08   78.0   0.99   0.97   1.02
  Ovaries                   32.6                                   88.2                                   37.0   0.99   1.12   0.31   0.29   1.09   1.03   35.4   1.04   1.04   1.00
  Prostate                  43.7                                   68.6                                   63.7   0.56   0.82   0.20   0.24   0.79   1.04   64.1   0.86   0.86   1.01
  Testis                    89.7                                   96.8                                   92.6   1.67   1.73   0.36   0.40   1.62   1.07   92.3   1.74   1.77   0.98
  Kidneys                   44.4                                   83.0                                   53.4   0.90   1.08   0.28   0.28   1.05   1.03   52.4   1.08   1.07   1.01
  Eye                       65.1                                   86.7                                   75.1   2.84   3.28   0.93   0.32   3.10   1.06   74.5   3.36   3.36   1.00
  Brain/nervous system      29.1                                   91.2                                   31.9   1.18   1.29   0.31   0.35   1.26   1.03   30.1   1.06   1.05   1.02
  thyroid gland             80.9                                   92.5                                   87.5   1.05   1.14   0.34   0.60   0.98   1.17   85.3   1.03   1.02   1.01
  Non-Hodgkin\'s lymphoma   42.1                                   83.7                                   50.3   0.85   1.02   0.29   0.37   0.97   1.05   47.8   0.96   0.94   1.02
  Multiple myeloma          21.3                                   77.9                                   27.3   1.20   1.54   0.54   0.34   1.46   1.05   24.8   1.37   1.38   0.99
  Leukaemia                 32.2                                   80.7                                   39.8   1.07   1.33   0.43   0.34   1.27   1.05   37.7   1.27   1.26   1.01
  Gallbladder               5.5                                    77.1                                   7.1    0.82   1.06   0.68   0.09   1.06   1.00   7.1    1.09   1.08   1.00
  Hodgkin\'s lymphoma       74.1                                   93.7                                   79.1   1.86   1.99   0.49   0.51   1.79   1.11   76.9   1.75   1.72   1.02

Abbreviations: Abs=absolute survival; Exp=expected survival; Rel=relative survival; SE~Abs~=standard error of absolute survival; SE~RG~=standard error of relative survival according to Greenwood formula; Corr~AbsExp~=correlation of absolute and expected survival in 10 000 bootstrap replications; SE~Exp~=standard error of expected survival; SE~RB~=standard error of relative survival according to bootstrap analysis

Standard errors are reported in % units.

Expected survival was computed according to Hakulinen\'s method.

###### Non-standardised absolute, expected and relative survival and age-standardised relative survival after 10 years of patients aged 15 or more years with a first diagnosis of common forms of cancer, Finland, 1989--1993[a](#t3-fn3){ref-type="fn"}

                            **Non-standardised 10-year survival**   **Age-standardised 10-year survival**                                                                         
  ------------------------- --------------------------------------- --------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Oral cavity               35.2                                    62.6                                    56.3   1.10   1.75   0.65   0.27   1.63   1.07   54.7   2.01   1.99   1.01
  Oesophagus                3.6                                     55.6                                    6.5    0.60   1.08   0.90   0.13   1.06   1.02   6.0    1.11   1.10   1.01
  Stomach                   12.0                                    56.9                                    21.1   0.47   0.83   0.42   0.21   0.81   1.03   19.1   0.88   0.86   1.02
  Colorectal                27.5                                    59.0                                    46.6   0.48   0.82   0.30   0.27   0.76   1.07   45.3   0.93   0.91   1.02
  Liver                     1.8                                     57.7                                    3.1    0.42   0.72   0.86   0.12   0.72   1.00   2.2    0.52   0.52   0.99
  Pancreas                  1.1                                     57.1                                    2.0    0.18   0.32   0.48   0.12   0.32   1.00   1.5    0.26   0.26   1.01
  Larynx                    33.2                                    65.0                                    51.0   2.01   3.09   1.04   0.25   2.93   1.05   50.2   3.54   3.49   1.01
  Lung                      3.7                                     60.5                                    6.0    0.19   0.31   0.24   0.15   0.31   1.01   5.3    0.29   0.29   1.01
  Skin melanoma             58.6                                    76.0                                    77.1   1.00   1.31   0.52   0.39   1.16   1.14   75.4   1.55   1.52   1.02
  Breast                    56.4                                    78.8                                    71.6   0.43   0.55   0.22   0.36   0.49   1.11   69.8   0.62   0.60   1.03
  Urinary bladder           34.3                                    55.3                                    61.9   0.80   1.44   0.45   0.37   1.28   1.12   56.3   1.53   1.49   1.03
  Cervix                    40.2                                    73.6                                    54.6   1.90   2.58   1.07   0.43   2.30   1.12   48.2   2.44   2.43   1.00
  Corpus uteri              57.5                                    74.5                                    77.2   0.92   1.24   0.44   0.39   1.09   1.14   74.7   1.38   1.34   1.03
  Ovaries                   25.3                                    76.2                                    33.2   0.91   1.20   0.52   0.28   1.15   1.05   29.9   1.12   1.12   1.00
  Prostate                  20.3                                    44.5                                    45.6   0.46   1.03   0.27   0.25   0.97   1.06   45.4   1.19   1.18   1.01
  Testis                    88.1                                    93.4                                    94.4   1.78   1.91   0.67   0.39   1.74   1.10   94.5   2.32   2.37   0.98
  Kidneys                   30.8                                    66.9                                    46.0   0.84   1.25   0.45   0.28   1.18   1.06   43.0   1.27   1.25   1.02
  Eye                       47.0                                    74.4                                    63.2   2.98   4.00   1.53   0.32   3.72   1.08   60.7   4.39   4.36   1.01
  Brain/nervous system      21.0                                    82.1                                    25.5   1.06   1.29   0.55   0.34   1.25   1.03   22.9   1.11   1.09   1.02
  Thyroid Gland             75.1                                    85.0                                    88.3   1.16   1.37   0.58   0.59   1.08   1.26   84.0   1.39   1.38   1.01
  Non-Hodgkin\'s lymphoma   29.3                                    68.7                                    42.7   0.78   1.14   0.46   0.36   1.07   1.07   38.4   1.13   1.12   1.01
  Multiple myeloma          8.2                                     58.9                                    13.8   0.80   1.36   0.80   0.33   1.31   1.04   10.4   1.06   1.07   0.99
  Leukaemia                 16.7                                    64.3                                    26.0   0.86   1.34   0.66   0.31   1.27   1.05   22.2   1.26   1.25   1.01
  Gallbladder               3.5                                     57.3                                    6.1    0.66   1.16   1.03   0.09   1.16   1.00   6.4    1.38   1.38   1.00
  Hodgkin\'s lymphoma       66.7                                    87.7                                    76.0   2.01   2.29   0.85   0.51   1.96   1.17   71.4   2.08   2.03   1.02

Abbreviations: Abs=absolute survival; Exp=expected survival; Rel=relative survival; SE~Abs~=standard error of absolute survival; SE~RG~=standard error of relative survival according to Greenwood formula; Corr~AbsExp~=correlation of absolute and expected survival in 10 000 bootstrap replications; SE~Exp~=standard error of expected survival; SE~RB~=standard error of relative survival according to bootstrap analysis.

Standard errors are reported in % units.

Expected survival was computed according to Hakulinen\'s method.

###### Non-standardised absolute, expected and relative survival and age-standardised relative survival after 5 years of patients aged 15 or more years with a first diagnosis of common forms of cancer, Finland, 1989--1993[a](#t4-fn3){ref-type="fn"}

                            **Non-standardised 5-year survival**   **Age-standardised 5-year survival**                                                                         
  ------------------------- -------------------------------------- -------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Oral cavity               51.0                                   79.5                                   64.2   1.14   1.44   0.53   0.21   1.42   1.01   63.9   1.50   1.48   1.01
  Oesophagus                5.5                                    79.6                                   6.9    0.73   0.92   1.09   0.16   0.89   1.03   6.6    0.89   0.88   1.00
  Stomach                   16.9                                   80.1                                   21.1   0.55   0.68   0.42   0.15   0.68   1.00   20.7   0.68   0.67   1.02
  Colorectal                39.4                                   79.5                                   49.5   0.53   0.66   0.24   0.16   0.66   1.00   49.3   0.68   0.67   1.02
  Liver                     3.0                                    81.1                                   3.8    0.54   0.67   1.77   0.15   0.66   1.00   3.5    0.62   0.64   0.97
  Pancreas                  1.8                                    83.7                                   2.1    0.23   0.27   0.92   0.19   0.27   1.02   2.0    0.26   0.26   1.00
  Larynx                    49.9                                   82.5                                   60.5   2.13   2.59   0.74   0.11   2.58   1.00   60.5   2.67   2.68   1.00
  Lung                      7.2                                    82.5                                   8.8    0.25   0.31   0.27   0.14   0.31   1.02   8.5    0.31   0.31   0.99
  Skin melanoma             71.0                                   87.8                                   80.9   0.92   1.05   0.35   0.26   1.02   1.02   80.5   1.09   1.07   1.02
  Breast                    72.2                                   89.5                                   80.6   0.39   0.43   0.15   0.21   0.43   1.01   80.3   0.45   0.45   1.01
  Urinary bladder           51.9                                   77.0                                   67.4   0.84   1.09   0.35   0.22   1.07   1.02   66.7   1.11   1.10   1.02
  Cervix                    48.7                                   89.7                                   54.3   1.94   2.16   0.62   0.30   2.09   1.03   53.1   2.01   2.00   1.01
  Corpus uteri              69.4                                   88.5                                   78.4   0.87   0.98   0.28   0.21   0.94   1.04   77.8   0.98   0.98   1.00
  Ovaries                   32.6                                   91.6                                   35.6   0.99   1.08   0.31   0.11   1.07   1.01   35.2   1.03   1.04   0.99
  Prostate                  43.7                                   68.5                                   63.8   0.56   0.82   0.23   0.18   0.81   1.02   63.9   0.86   0.85   1.01
  Testis                    89.7                                   97.2                                   92.2   1.67   1.73   0.34   0.19   1.70   1.02   92.2   1.73   1.80   0.96
  Kidneys                   44.4                                   84.6                                   52.4   0.90   1.06   0.31   0.15   1.04   1.02   52.1   1.06   1.07   1.00
  Eye                       65.1                                   87.8                                   74.2   2.84   3.24   0.90   0.17   3.23   1.00   74.0   3.30   3.32   0.99
  Brain/nervous system      29.1                                   95.5                                   30.5   1.18   1.23   0.26   0.19   1.23   1.01   30.1   1.06   1.06   1.00
  Thyroid gland             80.9                                   94.3                                   85.8   1.05   1.12   0.30   0.32   1.07   1.04   85.0   1.01   1.01   1.00
  Non-Hodgkin\'s lymphoma   42.1                                   87.4                                   48.1   0.85   0.97   0.29   0.17   0.98   1.00   47.4   0.94   0.94   0.99
  Multiple myeloma          21.3                                   82.3                                   25.8   1.20   1.46   0.61   0.28   1.42   1.02   24.5   1.35   1.34   1.01
  Leukaemia                 32.2                                   84.8                                   38.0   1.07   1.27   0.47   0.18   1.24   1.02   37.3   1.24   1.24   1.01
  Gallbladder               5.5                                    80.2                                   6.8    0.82   1.02   1.55   0.03   1.03   0.99   6.9    1.05   1.05   1.00
  Hodgkin\'s lymphoma       74.1                                   95.7                                   77.5   1.86   1.95   0.39   0.26   1.91   1.02   76.8   1.74   1.77   0.98

Abbreviations: Abs=absolute survival; Exp=expected survival; Rel=relative survival; SE~Abs~=standard error of absolute survival; SE~RG~=standard error of relative survival according to Greenwood formula; Corr~AbsExp~=correlation of absolute and expected survival in 10 000 bootstrap replications; SE~Exp~=standard error of expected survival; SE~RB~=standard error of relative survival according to bootstrap analysis.

Standard errors are reported in % units.

Expected survival was computed according to the Ederer II method.

###### Non-standardised absolute, expected and relative survival and age-standardised relative survival after 10 years of patients aged 15 or more years with a first diagnosis of common forms of cancer, Finland, 1989--1993[a](#t5-fn3){ref-type="fn"}

                            **Non-standardised 10-year survival**   **Age-standardised 10-year survival**                                                                         
  ------------------------- --------------------------------------- --------------------------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Oral cavity               35.2                                    62.4                                    56.5   1.10   1.75   0.88   0.31   1.68   1.04   55.0   2.04   2.02   1.01
  Oesophagus                3.6                                     63.8                                    5.6    0.60   0.94   2.39   0.01   0.95   0.98   5.6    1.00   0.99   1.00
  Stomach                   12.0                                    64.0                                    18.7   0.47   0.74   0.85   0.20   0.73   1.01   18.5   0.83   0.82   1.01
  Colorectal                27.5                                    61.4                                    44.8   0.48   0.78   0.46   0.25   0.77   1.02   44.8   0.91   0.91   1.00
  Liver                     1.8                                     70.7                                    2.5    0.42   0.58   3.05   0.25   0.57   1.03   2.2    0.52   0.52   0.99
  Pancreas                  1.1                                     73.7                                    1.5    0.18   0.25   2.42   0.16   0.25   1.01   1.4    0.25   0.25   0.98
  Larynx                    33.2                                    66.9                                    49.6   2.01   3.00   1.36   0.22   2.91   1.03   49.1   3.39   3.40   1.00
  Lung                      3.7                                     68.0                                    5.4    0.19   0.27   0.63   0.16   0.27   1.02   5.1    0.28   0.27   1.01
  Skin melanoma             58.6                                    77.0                                    76.0   1.00   1.29   0.62   0.29   1.27   1.02   75.2   1.54   1.53   1.01
  Breast                    56.4                                    79.7                                    70.8   0.43   0.54   0.27   0.28   0.52   1.05   69.7   0.62   0.61   1.02
  Urinary bladder           34.3                                    58.5                                    58.6   0.80   1.36   0.58   0.32   1.28   1.06   55.9   1.50   1.47   1.02
  Cervix                    40.2                                    81.7                                    49.2   1.90   2.32   1.16   0.28   2.23   1.04   47.4   2.29   2.30   1.00
  Corpus uteri              57.5                                    76.9                                    74.8   0.92   1.20   0.53   0.26   1.17   1.03   74.2   1.35   1.33   1.02
  Ovaries                   25.3                                    83.7                                    30.2   0.91   1.09   0.68   0.17   1.08   1.01   29.5   1.08   1.10   0.99
  Prostate                  20.3                                    44.3                                    45.7   0.46   1.03   0.35   0.25   1.00   1.03   44.8   1.17   1.14   1.02
  Testis                    88.1                                    94.1                                    93.6   1.78   1.90   0.70   0.17   1.90   1.00   94.1   2.29   2.44   0.94
  Kidneys                   30.8                                    70.2                                    43.9   0.84   1.19   0.62   0.26   1.14   1.04   42.5   1.25   1.24   1.01
  Eye                       47.0                                    76.7                                    61.3   2.98   3.88   1.67   0.27   3.75   1.04   59.6   4.13   4.16   0.99
  Brain/nervous system      21.0                                    92.1                                    22.7   1.06   1.15   0.57   0.08   1.15   1.00   22.6   1.08   1.08   1.00
  Thyroid gland             75.1                                    88.9                                    84.5   1.16   1.31   0.56   0.28   1.27   1.03   83.5   1.34   1.37   0.98
  Non-Hodgkin\'s lymphoma   29.3                                    76.4                                    38.4   0.78   1.03   0.60   0.19   1.02   1.01   37.6   1.08   1.08   1.00
  Multiple myeloma          8.2                                     71.1                                    11.5   0.80   1.13   1.25   0.24   1.10   1.02   10.2   1.01   1.03   0.98
  Leukaemia                 16.7                                    72.9                                    22.9   0.86   1.18   0.87   0.30   1.13   1.05   21.4   1.16   1.14   1.02
  Gallbladder               3.5                                     61.3                                    5.7    0.66   1.08   4.01   0.03   1.15   0.94   6.0    1.26   1.33   0.94
  Hodgkin\'s lymphoma       66.7                                    92.5                                    72.1   2.01   2.17   0.62   0.30   2.11   1.03   70.9   1.97   1.95   1.01

Abbreviations: Abs=absolute survival; Exp=expected survival; Rel=relative survival; SE~Abs~=standard error of absolute survival; SE~RG~=standard error of relative survival according to Greenwood formula; Corr~AbsExp~=correlation of absolute and expected survival in 10 000 bootstrap replications; SE~Exp~=standard error of expected survival; SE~RB~=standard error of relative survival according to bootstrap analysis.

Standard errors are reported in % units.

Expected survival was computed according to the Ederer II method.
